-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VW1zG2phPRDg4hRLtRHk42b2wkzZKQjfyUJwKRXD4BP/BU+Zu9Mb66I9O3EmFw1s vIiAaL4toXuTrxCAS6LqUw== 0001209191-10-031108.txt : 20100528 0001209191-10-031108.hdr.sgml : 20100528 20100528153628 ACCESSION NUMBER: 0001209191-10-031108 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100526 FILED AS OF DATE: 20100528 DATE AS OF CHANGE: 20100528 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gillespie Deirdre CENTRAL INDEX KEY: 0001354737 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24274 FILM NUMBER: 10866631 MAIL ADDRESS: STREET 1: 416 MARLBOROUGH STREET STREET 2: APT. 707 CITY: BOSTON STATE: MA ZIP: 02115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4365 EXECUTIVE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584526600 MAIL ADDRESS: STREET 1: 4365 EXECUTIVE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2010-05-26 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001354737 Gillespie Deirdre 4365 EXECUTIVE DRIVE, SUITE 300 SAN DIEGO CA 92121 1 1 0 0 President & CEO Common Stock 2010-05-26 4 A 0 437649 0.03 A 437649 D Series C-1 Convertible Preferred Stock 0.015 2010-05-26 4 A 0 104 1000.00 A 2010-12-03 Common Stock 6933368 104 D Series C-2 Convertible Pfd Stock Warrants (right to buy) 1000.00 2010-05-26 4 A 0 208 0.00 A 2010-05-26 2013-05-26 Series C-2 Convertible Preferred Stock 208 208 D Series D-1 Convertible Pfd Stock Warrants (right to buy) 1000.00 2010-05-26 4 A 0 104 0.00 A 2010-05-26 2013-05-26 Series D-1 Convertible Preferred Stock 104 104 D The Series C-1 Convertible Preferred Stock (the "Series C-1 Stock") is initially convertible into shares of common stock of La Jolla Pharmaceutical Company at a price per share of $0.015, but such conversion price will be adjusted for certain events, such as stock splits, stock dividends, reclassifications and recapitalizations, and is subject to full-ratchet anti-dilution protection such that any subsequent issuance of common stock below $0.015 automatically adjusts the conversion price of the Series C-1 Stock to such lower price. The Series C-1 Stock does not have a set expiration date, although the holders of such stock may require the Company to redeem the Series C-1 Stock upon certain events. Upon exercise of these Series C-2 Convertible Preferred Stock Warrants, Dr. Gillespie will receive up to 208 shares of Series C-2 Convertible Preferred Stock and warrants to purchase up to 208 shares of Series D-2 Convertible Preferred Stock. /s/ Deirdre Y. Gillespie 2010-05-28 -----END PRIVACY-ENHANCED MESSAGE-----